All In Biotech

Drug Trial Radar · NCT05181462

Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.

A Randomized Non-comparative Open-label Phase 1b/2 Study of Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. "TRIFOUR Study"

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

117

Actual

Start

Jan 11, 2022

Primary completion

Apr 9, 2026

Study completion May 8, 2026

Sponsor

Lead sponsor
Cantargia ABIndustry
Sponsor type
Industry
Collaborators
Spanish Breast Cancer Research Group
First posted
Jan 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) worldwide. The term triple negative means that tumor growth is not stimulated by the hormones estrogen and progesterone, nor by the HER2 protein, so unlike other types of BC, TNBC, which is an aggressive form of BC, does not have specific effective therapies available being the least common form of BC and the most difficult to treat. Advanced or metastatic TNBC is treated with combinations of platinum-based chemotherapy with taxanes or gemcitabine with a 5-year survival rate of 12%. Recent studies have shown that TNBC expresses Interleukin 1 Receptor Accessory Protein (IL1RAP) at higher levels than other forms of BC. Nadunolimab is a fully humanized monoclonal antibody that blocks the signals that occur within the cell produced by IL1RAP protein, thereby impairing the cancer cells' ability to secrete tumor stimulating substances, in turn reducing the tumor, inflammation and tumor progression. On the other hand, it is an antibody designed to activate the immune system to fight cancer cells. This clinical trial is divided into two phases, phase Ib in which it is expected to include up to 15 patients and phase II in which it is expected to include 102 patients. The main purpose of phase Ib is to ensure that the combination of nadunolimab plus chemotherapy (gemcitabine plus carboplatin) is safe and determine the highest dose of nadunolimab that can be given safely without causing serious side effects. If the pre-specified objectives in this part are achieved, the trial will be expanded to a randomized phase II, to evaluate the efficacy of the combination of nadunolimab plus gemcitabine plus carboplatin, compared to a control group that will receive gemcitabine plus carboplatin only.

Conditions

  • Triple Negative Breast Cancer

Interventions

  • CarboplatinDrug

    Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8/15, in cycles of 3-4 weeks

  • GemcitabineDrug

    Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks

  • NadunolimabDrug

    Nadunolimab escalation (DL -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8/15, in cycles of 3-4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence rate of Dose Limiting Toxicity (DLT) within the first cycle of nadunolimab in combination with gemcitabine plus carboplatinTime frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Objective Response Rate (ORR)Time frame: Through study completion, an average of 58 months

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Virgen de las Nieves

    Granada, Andalusia, Spain

  • Hospital Universitario Clinico San Cecilio

    Granada, Andalusia, Spain

  • Complejo Hospitalario de Jaén

    Jaén, Andalusia, Spain

  • Hospital Universitario Virgen De La Victoria

    Málaga, Andalusia, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Andalusia, Spain

  • Hospital Universitario Virgen Del Rocío

    Seville, Andalusia, Spain

  • Hospital Clínico Universitario Lozano Blesa

    Zaragoza, Aragon, Spain

  • Onkologikoa

    Donostia / San Sebastian, Basque Country, Spain

  • Complejo Hospitalario Universitario de Albacete

    Albacete, Castille-La Mancha, Spain

  • Hospital Universitario de Toledo

    Toledo, Castille-La Mancha, Spain

  • Hospital del Mar

    Barcelona, Catalonia, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Catalonia, Spain

  • ICO Institut Catalá d'Oncologia de L´Hospitalet

    Hospitalet de Llobregat, Barcelona, Catalonia, Spain

  • Hospital Universitario Arnau de Vilanova Lleida

    Lleida, Catalonia, Spain

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, Galicia, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, Galicia, Spain

  • Hospital Materno Infantil de Gran Canaria

    Las Palmas de Gran Canaria, Las Palmas, Spain

  • Hospital Universitario Gregorio Marañón

    Madrid, Madrid, Spain

  • Hospital Clínico San Carlos

    Madrid, Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain

  • Clínica Universidad de Navarra

    Pamplona, Navarre, Spain

  • Hospital Universitario San Juan de Alicante

    Alicante, Valencia, Spain

  • Fundación Instituto Valenciano de Oncología

    Valencia, Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.